Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07359014 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapse Multiple Myeloma

Interventions

OTHER: Dual CD19/BCMA CAR-T

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]